ALPHAGAN SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

BRIMONIDINE TARTRATE

Inapatikana kutoka:

ABBVIE CORPORATION

ATC kanuni:

S01EA05

INN (Jina la Kimataifa):

BRIMONIDINE

Kipimo:

0.2%

Dawa fomu:

SOLUTION

Tungo:

BRIMONIDINE TARTRATE 0.2%

Njia ya uendeshaji:

OPHTHALMIC

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

ALPHA-ADRENERGIC AGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0131859001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

1997-11-24

Tabia za bidhaa

_ALPHAGAN (brimonidine tartrate) _
_Page 1 of 26 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALPHAGAN®
brimonidine tartrate ophthalmic solution
Solution, 0.2% w/v, for ophthalmic use
Relatively Selective α
2
-Adrenoceptor Agonist
ATC Code: S01EA05
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Quebec
H4S 1Z1
Submission Control Number: 267088
Date of Initial Authorization:
NOV 24, 1997
Date of Revision:
SEP
29, 2022
_ALPHAGAN (brimonidine tartrate) _
_Page 2 of 26 _
_ _
RECENT MAJOR LABEL CHANGES
None at the time of the most recent authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
.............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................ 4
4.4
Administration
.........................................................................................................
4
4.5
Missed Dose
..